SOD1 and asthma: Ebselen’s on-target SOD1 pharmacological chaperone activity, in combination with its usage history and positive secondary pharmacology reminiscent of edaravone, indicates that it is a very promising lead not only in the search for therapeutics, which can modulate pathogenic SOD1 behaviour in ALS, but also asthma.